TrialPharmacotherapy2022

Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.

Dana Furstenau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.